Navigation Links
Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology
Date:3/14/2011

delivered with Inovio's electroporation device; the 12-patient comparison group will receive standard-of-care treatment alone. The study has received approval from the Swedish Medical Products Agency and local ethical committee.

"If we can repeat the Phase I results in this phase IIb study there is certainly a possibility that vaccination with ChronVac-C® before drug therapy could become a part of the standard of care therapy for patients with chronic hepatitis C-virus infection. In particular, we hope that vaccination with this novel therapy will result in a considerable shortening of the duration of interferon and ribavirin treatment," said Anders Vahlne, CEO of ChronTech Pharma AB.

Dr. J. Joseph Kim, Inovio's president and CEO, said: "We are encouraged by the phase I results showing the improved cure rate in patients who received the HCV vaccine followed by a SOC drug therapy. Any improvement to the HCV standard of care response rates would be well-received by HCV patients and practitioners. We are pleased to collaborate in this advancement of ChronVac-C®, using Inovio's innovative delivery technology, into Phase II."

About Hepatitis C Virus

Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States, where approximately 3.5 million persons have been chronically infected. Worldwide, about 300 million people have been infected with HCV. Based on current statistics for hepatitis C, it is estimated that 8,000 to 10,000 people die each year from chronic liver disease caused by this condition. Chronic HCV infection is the leading indication for liver transplants in the United States. Total health costs associated with hepatitis C virus in the U.S. are estimated at more than $15 billion per year. No vaccine for HCV is currently available.

About Inovio's Electroporation-Based Delivery Technology

Inovio's electroporation-based DNA delivery systems can increase
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
2. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
3. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
6. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
7. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
8. Onyx Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
9. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
10. Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
11. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, ... an update on its pipeline and new product ... expects to initiate a Phase 2a study of ... developed for the management of patients with acute ... Staccato -based product candidates for development - ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
(Date:8/1/2014)... 2014 A new study published ... may contribute to the development of colorectal cancer in ... The study was authored by Alberto Martin of the ... cause intestinal cells to multiply and create tumors in ... , “What’s interesting about this study,” said Shahab ...
(Date:8/1/2014)... Canadian, OK (PRWEB) August 01, 2014 ... graduate from the program at the drug rehab center ... in the year 2001, Narconon Arrowhead is the flagship ... come from across the United States for services there. ... the center has recent outcome studies as well as ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... recently announced the addition of a comprehensive report ... titled ‘Infusion System Market (Large Volume, Disposable, Syringe, ... Share, Growth, Trends And Forecast, 2013 – 2019’ ... website http://www.transparencymarketresearch.com . , To begin with, ...
(Date:8/1/2014)... HealthDay Reporter , THURDAY, July ... healthier than school cafeteria fare, a new study suggests. ... lunches third and fourth graders brought from home met three ... "Our findings are similar to results of other studies of ... that high-calorie packaged foods and beverages are more common than ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although older women ... make asthma care a priority, according to a new study. ... from asthma much more than men over 65," concluded Dr. ... of Allergy, Asthma and Immunology (ACAAI), in an organization news ... age 65 years and older is nearly four times higher ...
Breaking Medicine News(10 mins):Health News:Carbs May Contribute to Colon Cancer 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3Health News:Older Women With Asthma Face Worse Health Outcomes 2
... April 22 Aida,Pharmaceuticals, Inc. (OTC Bulletin ... investor-focused corporate synopsis on its English,language website, ... as a,pdf document. The synopsis details Aida ... line, the drugs in its,development pipeline, as ...
... leads to adverse reactions identified, officials add , , MONDAY, ... now been found in at least 10 countries, not ... to ensure the safety of the blood thinner, U.S. ... contaminated lots of the blood thinner have been traced ...
... Available in Smaller Package for Healthy Snacking, MINDEN, ... the maker of the award-winning Detour(R) bar, today announced,the ... their top,selling Detour Caramel Peanut Bar(TM). The snack size ... choice for energy seekers living a,healthy lifestyle. With seven ...
... The American College of Allergy,Asthma & Immunology ... surveys that highlight the importance of improving care ... and other important,information for physicians and patients are ... like Sepracor who are,committed to driving the dialogue ...
... SAN JUAN, Puerto Rico, April 22 Triple-S,Management Corporation ... plans,to release financial results for the first quarter ended ... 2008. Ramon M. Ruiz-Comas, President and,Chief Executive Officer, and ... host a conference call to discuss these,results and the ...
... Formation Capital, LLC is,pleased to announce that ... joined the company as Senior Executive Vice President ... be leading the day-to-day,operations and direction of the ... leading change, building shareholder value, and managing Board,and ...
Cached Medicine News:Health News:Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website 2Health News:FDA: Contaminated Heparin Found in 11 Countries 2Health News:FDA: Contaminated Heparin Found in 11 Countries 3Health News:FDA: Contaminated Heparin Found in 11 Countries 4Health News:Detour(R) Unveils Snack Size Protein Bar 2Health News:Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast 2Health News:Damian Dell'Anno Joins Formation Capital as Chief Operating Officer 2
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
S.O.C. Medium...
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: